Abstract
..
Main
..
Feedback
Home
c19
early
.org
COVID-19 treatment
research
Diet
Diet
(more..)
Analgesics
⏵
Acetaminophen
Meta
Aspirin
Meta
Ibuprofen
Meta
Indomethacin
Meta
Close
Minerals
⏵
Selenium
Meta
Zinc
Meta
Close
Antiandrogens
⏵
All
Meta
Proxalutamide
Meta
Spironolactone
Meta
Close
Monoclonals
⏵
Adintrevimab
Meta
Amubarv../r..
Meta
BMS mAbs
Meta
Bamlaniv../e..
Meta
Bebtelovimab
Meta
Casirivimab/i..
Meta
Pemivibart
Meta
Ravulizumab
Meta
Regdanvimab
Meta
SA58
Meta
Sarilumab
Meta
Sipavibart
Meta
Sotrovimab
Meta
Tixagev../c..
Meta
Vilobelimab
Meta
Close
Antihistamines
⏵
All H1RAs
Meta
Azelastine
Meta
Famotidine
Meta
Close
Mpro inhibitors
⏵
Atilotrelvir
Meta
Ensitrelvir
Meta
Ibuzatrelvir
Meta
Leritrelvir
Meta
Lufotrelvir
Meta
Olgotrelvir
Meta
Paxlovid
Meta
Pomotrelvir
Meta
Xiannuoxin
Meta
Close
Budesonide
Meta
Naso/orophar..
⏵
Alkalinization
Meta
Cetylpyridin..
Meta
Chlorhexidine
Meta
Chlorphenira..
Meta
HH-120
Meta
Hydrogen Per..
Meta
Iota-carragee..
Meta
NaCl
Meta
Nitric Oxide
Meta
Phthalocyan..
Meta
Povidone-Iod..
Meta
Sodium Bicar..
Meta
Close
Colchicine
Meta
Nigella Sativa
Meta
Conv. Plasma
Meta
Nitazoxanide
Meta
Curcumin
Meta
PPIs
Meta
Fluvoxamine
Meta
Quercetin
Meta
Hydroxychlor..
Meta
RdRp inhibitors
⏵
Azvudine
Meta
Bemnifosbuvir
Meta
Deuremidevir
Meta
Favipiravir
Meta
Molnupiravir
Meta
Remdesivir
Meta
Close
Ivermectin
Meta
TMPRSS2 inh.
⏵
All
Meta
Bromhexine
Meta
Camostat
Meta
Nafamostat
Meta
Close
Lifestyle
⏵
Diet
Meta
Exercise
Meta
Sleep
Meta
Sun
Meta
Close
Thermotherapy
Meta
Melatonin
Meta
Vitamins
⏵
Vitamin A
Meta
Vitamin B9
Meta
Vitamin B12
Meta
Vitamin C
Meta
Vitamin D
Meta
Vitamin K
Meta
Close
Metformin
Meta
More
⏵
Andrograph..
Meta
Artemisinin
Meta
Cannabidiol
Meta
Dexamethas..
Meta
Ensovibep
Meta
Lactoferrin
Meta
Lopinavir/r..
Meta
Losartan
Meta
Masks
Meta
Montelukast
Meta
N-acetylcys..
Meta
Niclosamide
Meta
Peg.. Lambda
Meta
Probiotics
Meta
Propolis
Meta
Resveratrol
Meta
Tocilizumab
Meta
UDCA
Meta
Close
Home
Adoption
Other Treatments
@CovidAnalysis
Loading...
Analgesics
⏵
Acetaminophen
Aspirin
Ibuprofen
Indomethacin
Antiandrogens
⏵
All
Proxalutamide
Spironolactone
Antihistamines
⏵
All H1RAs
Azelastine
Famotidine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
⏵
Diet
Exercise
Sleep
Sun
Melatonin
Metformin
Minerals
⏵
Selenium
Zinc
Monoclonals
⏵
Adintrevimab
Amubarvimab/romlusevimab
BMS mAbs
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Pemivibart
Ravulizumab
Regdanvimab
SA58
Sarilumab
Sipavibart
Sotrovimab
Tixagevimab/cilgavimab
Vilobelimab
Mpro inhibitors
⏵
Atilotrelvir
Ensitrelvir
Ibuzatrelvir
Leritrelvir
Lufotrelvir
Olgotrelvir
Paxlovid
Pomotrelvir
Xiannuoxin
Naso/orophar..
⏵
Alkalinization
Cetylpyridinium Chloride
Chlorhexidine
Chlorpheniramine
HH-120
Hydrogen Peroxide
Iota-carrageenan
NaCl
Nitric Oxide
Phthalocyanine
Povidone-Iodine
Sodium Bicarbonate
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
⏵
Azvudine
Bemnifosbuvir
Deuremidevir
Favipiravir
Molnupiravir
Remdesivir
TMPRSS2 inh.
⏵
All
Bromhexine
Camostat
Nafamostat
Thermotherapy
Vitamins
⏵
Vitamin A
Vitamin B9
Vitamin B12
Vitamin C
Vitamin D
Vitamin K
More
⏵
Andrographolide
Artemisinin
Cannabidiol
Dexamethasone
Ensovibep
Lactoferrin
Lopinavir/ritonavir
Losartan
Masks
Montelukast
N-acetylcysteine
Niclosamide
Peginterferon Lambda
Probiotics
Propolis
Resveratrol
Tocilizumab
Ursodeoxycholic acid
Supplementary Data — Healthier diets reduce COVID-19 risk: real-time meta analysis of 30 studies
@CovidAnalysis
, December 2025,
Version 36
V36
PDF
All
Studies
All
Treatments
Feedback
https://c19early.org/dtmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Mahto
20%
0.80 [0.49-1.21]
IgG+
23/206
70/483
Improvement, RR [CI]
Treatment
Control
Naushin
40%
0.60 [0.50-0.71]
seropositive
n/a
n/a
Kim
72%
0.28 [0.10-0.82]
m/s case
41 (n)
527 (n)
Kim
59%
0.41 [0.16-0.99]
m/s case
46 (n)
522 (n)
Kim
19%
0.81 [0.56-1.15]
cases
41 (n)
527 (n)
Kim
23%
0.77 [0.55-1.08]
cases
46 (n)
522 (n)
Merino
41%
0.59 [0.47-0.74]
severe case
148,142 (n)
148,143 (n)
Merino
18%
0.82 [0.78-0.86]
cases
148,142 (n)
148,143 (n)
Merino
9%
0.91 [0.88-0.94]
cases
148,142 (n)
148,143 (n)
Moludi
92%
0.08 [0.05-0.19]
cases
n/a
n/a
Ahmadi
-3%
1.03 [0.77-1.39]
death
185/206,286
62/75,264
Nguyen
15%
0.85 [0.75-0.96]
symp. case
345/1,054
433/1,082
Yamamoto
66%
0.34 [0.13-0.85]
cases
4/20
19/32
Magaña
53%
0.47 [0.22-0.99]
death
58 (n)
31 (n)
Jagielski
82%
0.18 [0.04-0.65]
cases
4/40
9/20
Perez-Araluce
78%
0.22 [0.03-1.77]
severe case
1/1,103
10/3,300
Perez-Araluce
15%
0.85 [0.62-1.15]
symp. case
52/1,103
214/3,300
Perez-Araluce
20%
0.80 [0.60-1.07]
cases
58/1,103
248/3,300
Firoozi
65%
0.35 [0.28-0.43]
cases
case control
per unit E-DII change
Hou
72%
0.28 [0.04-1.95]
severe case
1/22
78/487
Hou
11%
0.89 [0.58-1.36]
m/s case
11/22
273/487
Hou
74%
0.26 [0.10-0.67]
severe case
0/9
47/127
Hou
35%
0.65 [0.43-0.99]
m/s case
5/9
108/127
Zargarzadeh
77%
0.23 [0.11-0.50]
severe case
89 (n)
80 (n)
Yue
19%
0.81 [0.69-0.94]
cases
n/a
n/a
Yue
21%
0.79 [0.67-0.94]
cases
n/a
n/a
Yue
29%
0.71 [0.61-0.83]
cases
n/a
n/a
Yue
12%
0.88 [0.76-1.02]
cases
n/a
n/a
Zhou
16%
0.84 [0.78-0.91]
cases
1,321/10,254
1,935/10,253
Ebrahimzadeh
69%
0.31 [0.14-0.68]
severe case
n/a
n/a
Ebrahimzadeh
56%
0.44 [0.18-1.06]
hosp.
n/a
n/a
Ebrahimzadeh
68%
0.32 [0.15-0.68]
no recov.
n/a
n/a
Tadbir Vajargah
67%
0.33 [0.16-0.69]
severe case
83 (n)
83 (n)
Tadbir Vajargah
72%
0.28 [0.14-0.58]
severe case
83 (n)
83 (n)
Tadbir Vajargah
75%
0.25 [0.12-0.53]
severe case
83 (n)
83 (n)
Reis
75%
0.25 [0.12-0.52]
hosp.
17/380
21/166
Zhao
24%
0.76 [0.53-1.09]
death
39,230 (n)
39,231 (n)
Zhao
30%
0.70 [0.50-0.99]
death
39,230 (n)
39,231 (n)
Zhao
28%
0.72 [0.60-0.86]
severe case
39,230 (n)
39,231 (n)
Zhao
29%
0.71 [0.60-0.85]
severe case
39,230 (n)
39,231 (n)
Zhao
15%
0.85 [0.81-0.91]
cases
39,230 (n)
39,231 (n)
Zhao
9%
0.91 [0.85-0.96]
cases
39,230 (n)
39,231 (n)
Mohajeri
25%
0.75 [0.63-0.88]
progression
62/105
392/495
Mohajeri
51%
0.49 [0.40-0.60]
progression
50/105
482/495
Mohajeri
70%
0.30 [0.21-0.43]
progression
23/105
365/495
Mohajeri
-10%
1.10 [1.03-1.17]
progression
98/105
421/495
Mohajeri
53%
0.47 [0.36-0.61]
progression
38/105
380/495
Mohajeri
26%
0.74 [0.58-0.94]
progression
44/105
280/495
Wang
9%
0.91 [0.72-1.14]
PASC
124/318
218/480
LONG COVID
Wang
49%
0.51 [0.33-0.78]
PASC
188 (n)
66 (n)
LONG COVID
Zamanian
81%
0.19 [0.07-0.55]
hosp.
case control
Barania Adabi
99%
0.01 [0.00-0.21]
ICU
0/125
37/125
Barania Adabi
98%
0.02 [0.00-0.31]
ICU
0/125
26/125
Aghajani
88%
0.12 [0.04-0.29]
severe case
case control
Wang
45%
0.55 [0.29-1.03]
severe case
81 (n)
67 (n)
Wang
32%
0.68 [0.49-0.97]
viral+
81 (n)
67 (n)
Micek
70%
0.30 [0.07-1.13]
cases
32 (n)
21 (n)
Pavlidou
55%
0.45 [0.41-0.51]
cases
2,609 (n)
2,588 (n)
Darand
37%
0.63 [0.42-0.95]
cases
113 (n)
155 (n)
HawryĆkowicz
77%
0.23 [0.09-0.56]
hosp.
183 (n)
183 (n)
Diet COVID-19 outcomes
c19
early
.org
December 2025
Favors healthy diet
Favors control
Fig. S1.
All outcomes.